Trial Profile
Phase I Study of Combination Therapy With S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms SIRB2
- 04 Mar 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Dec 2017 New trial record